Literature DB >> 22931329

Natalizumab-associated progressive multifocal leukoencephalopathy.

Nicasio Mancini, Massimo Clementi, Roberto Burioni.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22931329     DOI: 10.1056/NEJMc1207116

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.

Authors:  Roberta Antonia Diotti; Ruggero Capra; Lucia Moiola; Valeria Caputo; Nicola De Rossi; Francesca Sangalli; Vittorio Martinelli; Roberto Burioni; Massimo Clementi; Nicasio Mancini
Journal:  Viruses       Date:  2016-05-07       Impact factor: 5.048

Review 2.  Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis.

Authors:  Milan Buc
Journal:  Mediators Inflamm       Date:  2013-05-12       Impact factor: 4.711

Review 3.  Multiantibody strategies for HIV.

Authors:  Andrew Hiatt; Larry Zeitlin; Kevin J Whaley
Journal:  Clin Dev Immunol       Date:  2013-06-06

Review 4.  Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII).

Authors:  Giuseppe Sautto; Nicasio Mancini; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-11-08       Impact factor: 5.048

5.  Human monoclonal antibodies as a new class of antiinfective compounds.

Authors:  Roberto Burioni; Alois B Lang; J Donald Capra
Journal:  Clin Dev Immunol       Date:  2013-09-11

Review 6.  Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?

Authors:  Mancini Nicasio; Giuseppe Sautto; Nicola Clementi; Roberta A Diotti; Elena Criscuolo; Matteo Castelli; Laura Solforosi; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-09-24       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.